Literature DB >> 6627600

Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13.

J W Wei, R A Hickie, D J Klaassen.   

Abstract

The effects of anticalmodulin agents, namely trifluoperazine (TFP) and two naphthalene sulfonamide derivatives (W-7 and W-13), were tested on the growth of a human breast cancer cell line (MDA-MB-231) using a soft agar clonogenic assay. The results of this in vitro study reveal that TFP, W-7, and W-13 had the ability to inhibit the colony formation from this cell line. The inhibitory effect was greater when the cancer cells were exposed to these agents continuously than when the cells were exposed to the drugs for 1 h. The IC50 values for TFP, W-7, and W-13 in continuous exposure were about 18, 30, and 38 microM, respectively, whereas the corresponding values for 1-h exposure were 50, 53, and 70 microM, respectively. These findings suggest that anticalmodulin agents can inhibit the growth of human cancer cells at relatively low concentrations in vitro. Whether effective antitumor concentrations of these drugs can be achieved in vivo remains a subject for further study.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6627600     DOI: 10.1007/bf00254251

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  Relationship between changes in the calcium dependent regulatory protein and adenylate cyclase during viral transformation.

Authors:  D C LaPorte; S Gidwitz; M J Weber; D R Storm
Journal:  Biochem Biophys Res Commun       Date:  1979-02-28       Impact factor: 3.575

2.  Breast tumor cell lines from pleural effusions.

Authors:  R Cailleau; R Young; M Olivé; W J Reeves
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

3.  Calcium and magnesium content of rat liver and Morris Hepatoma 5123 tc.

Authors:  R A Hickie; H Kalant
Journal:  Cancer Res       Date:  1967-06       Impact factor: 12.701

4.  Calmodulin and cell proliferation.

Authors:  Y Sasaki; H Hidaka
Journal:  Biochem Biophys Res Commun       Date:  1982-01-29       Impact factor: 3.575

5.  Activity-structure relationship of calmodulin antagonists, Naphthalenesulfonamide derivatives.

Authors:  H Hidaka; M Asano; T Tanaka
Journal:  Mol Pharmacol       Date:  1981-11       Impact factor: 4.436

6.  Increased content of calmodulin in Morris hepatoma 5123 t.c. (h).

Authors:  J W Wei; R A Hickie
Journal:  Biochem Biophys Res Commun       Date:  1981-06       Impact factor: 3.575

7.  Calmodulin stimulates DNA synthesis by rat liver cells.

Authors:  A L Boynton; J F Whitfield; J P MacManus
Journal:  Biochem Biophys Res Commun       Date:  1980-07-31       Impact factor: 3.575

8.  Calcium: calmodulin and cancer.

Authors:  W E Criss; S Kakiuchi
Journal:  Fed Proc       Date:  1982-05

9.  Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro.

Authors:  B R Brinkley; P T Beall; L J Wible; M L Mace; D S Turner; R M Cailleau
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

Review 10.  Calcium ions and the control of proliferation in normal and cancer cells.

Authors:  A C Durham; J M Walton
Journal:  Biosci Rep       Date:  1982-01       Impact factor: 3.840

View more
  16 in total

1.  Free calcium and calmodulin levels in acinar carcinoma and normal acinar cells of rat pancreas.

Authors:  J L Chien; J R Warren
Journal:  Int J Pancreatol       Date:  1988-03

2.  Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine.

Authors:  W N Hait; S Morris; J S Lazo; R J Figlin; H J Durivage; K White; P E Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Marker gene screening for human mesenchymal stem cells in early osteogenic response to bone morphogenetic protein 6 with DNA microarray.

Authors:  Shien Zou; Shaofen Zhang; Qiqi Long; Yuankui Cao; Wei Zhang
Journal:  Genet Test Mol Biomarkers       Date:  2013-06-25

Review 4.  Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease.

Authors:  S M Cabarcas; E M Hurt; W L Farrar
Journal:  Curr Mol Med       Date:  2010-11       Impact factor: 2.222

5.  Calmodulin Lobes Facilitate Dimerization and Activation of Estrogen Receptor-α.

Authors:  Zhigang Li; Yonghong Zhang; Andrew C Hedman; James B Ames; David B Sacks
Journal:  J Biol Chem       Date:  2017-02-07       Impact factor: 5.157

6.  Calmodulin content in human central nervous system tumors.

Authors:  A J Bridges; A K Ho
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

7.  Antitumor effects of ketoconazole and trifluoperazine in murine T-cell lymphomas.

Authors:  S Naftalovich; E Yefenof; Y Eilam
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin.

Authors:  W N Hait; L Grais; C Benz; E C Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells.

Authors:  Eugenia Cifuentes; Jennifer M Mataraza; Barbara A Yoshida; Mani Menon; David B Sacks; Evelyn R Barrack; G Prem-Veer Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

10.  Calcium antagonism by the antioestrogen tamoxifen.

Authors:  A Lipton; I D Morris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.